Transdermal Photothermal Sterilization and Abscess Elimination Research of BSA-CuS Nanoparticles in vivo

Amino acid-mediated amorphous copper sulphide with enhanced photothermal conversion efficiency for antibacterial application

Pathogenic bacteria in daily life, such as Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli), often seriously affect human life and health. The extensive use of antibiotics has led to the emergence of drug-resistant bacteria, so it is urgent to develop efficient and non-drug-resistant sterilization methods. Here, we use small-molecule cysteine (Cys) as an auxiliary agent to synthesize spherical porous amorphous CuS-Cysteine (CuS-C) nanoparticles, which have good dispersion in aqueous solutions, and explore the reaction mechanism of Cys-induced CuS synthesis. The synthesized composite nanomaterials have strong near-infrared light absorption ability and efficient photothermal conversion ability and can effectively ablate pathogenic bacteria under the irradiation of an 808 nm laser. In addition, antibacterial experiments showed that CuS-C composites had no bactericidal effect without near-infrared light, but they had a good photothermal bactericidal effect on S. aureus and E. coli under radiation conditions. Considering the simple synthesis process, strong photothermal conversion ability, low cost, and suitability for large-scale production, CuS-C nanocomposites, as a promising antibacterial material, will provide a feasible scheme for the treatment of drug-resistant pathogens.

In vivo synergistic tumor therapies based on copper sulfide photothermal therapeutic nanoplatforms

Tumor cells may be eliminated by increasing their temperature. This is achieved via photothermal therapy (PTT) by penetrating the tumor tissue with near-infrared light and converting light energy into heat using photothermal agents. Copper sulfide nanoparticles (CuS NPs) are commonly used as PTAs in PTT. In this review, we aimed to discuss the synergism between tumor PTT with CuS NPs and other therapies such as chemotherapy, radiotherapy, dynamic therapies (photodynamic, chemodynamic, and sonodynamic therapy), immunotherapy, gene therapy, gas therapy, and magnetic hyperthermia. Furthermore, we summarized the results obtained with a combination of two treatments and at least two therapies, with PTT as one of the included therapies. Finally, we summarized the benefits and drawbacks of various therapeutic options and state of the art CuS-based PTT and provided future directions for such therapies.

Preclinical safety and hepatotoxicity evaluation of biomineralized copper sulfide nanoagents

Albumin-biomineralized copper sulfide nanoparticles (Cu_2-xS NPs) have attracted much attention as an emerging phototheranostic agent due to their advantages of facile preparation method and high biocompatibility. However, comprehensive preclinical safety evaluation is the only way to meet its further clinical translation. We herein evaluate detailedly the safety and hepatotoxicity of bovine serum albumin-biomineralized Cu_2-xS (BSA@Cu_2-xS) NPs with two different sizes in rats. Large-sized (LNPs, 17.8 nm) and small-sized (SNPs, 2.8 nm) BSA@Cu_2-xS NPs with great near-infrared absorption and photothermal conversion efficiency are firstly obtained. Seven days after a single-dose intravenous administration, SNPs distributed throughout the body are cleared primarily through the feces, while a large amount of LNPs remained in the liver. A 14-day subacute toxicity study with a 28-day recovery period are conducted, showing long-term hepatotoxicity without recovery for LNPs but reversible toxicity for SNPs. Cellular uptake studies indicate that LNPs prefer to reside in Kupffer cells, leading to prolonged and delayed hepatotoxicity even after the cessation of NPs administration, while SNPs have much less Kupffer cell uptake. RNA-sequencing analysis for gene expression indicates that the inflammatory pathway, lipid metabolism pathway, drug metabolism-cytochrome P450 pathway, cholesterol/bile acid metabolism pathway, and copper ion transport/metabolism pathway are compromised in the liver by two sizes of BSA@Cu_2-xS NPs, while only SNPs show a complete recovery of altered gene expression after NPs discontinuation. This study demonstrates that the translational feasibility of small-sized BSA@Cu_2-xS NPs as excellent nanoagents with manageable hepatotoxicity.